retatrutide or ozempic vs Zepound vs Next-Gen GLP-1 after Ozempic: Retatrutide

The obesity drug market is entering new phases, which includes Eli Lilly and Company advancing retatrutide, a next-generation triple-G therapy that could outperform its own marketed dual agonist Zepbound (tirzepatide)

Eating slowly and avoiding high-fat or very large meals helps significantly

What body-composition changes

Eating smaller meals more slowly may help reduce stomach irritation

A new lower dose Notably, Lilly also tested a lower 4-milligram dose not used in other trials, and it helped patients lose 19% of their weight, or 47.2 pounds, over 80 weeks

Your strategy is built around the specific treatments you offer and the patients you want to reach